Eye­ing a trio of tri­al ini­ti­a­tions, Jim Wilson's gene ther­a­py start­up woos Bruce Gold­smith from Deer­field as CEO

Pas­sage Bio — Jim Wil­son’s self-de­scribed “lega­cy com­pa­ny” — has wooed a sea­soned biotech ex­ec­u­tive to steer the clin­i­cal en­try of its first three gene ther­a­py pro­grams.

Bruce Gold­smith jumps to the helm of Pas­sage af­ter a brief CEO stint at Civet­ta, a can­cer-fo­cused start­up he helped launch while a ven­ture part­ner at Deer­field. He takes over from Or­biMed part­ner and in­ter­im chief Stephen Squin­to, who will now lead the R&D team.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER